SWOG clinical trial number
SWOG-8704
Neoadjuvant Methotrexate, Cisplatin and Vinblastine (MCV) Followed by Concomitant Cisplatin/Radiotherapy for Unresectable Localized Bladder Cancer Patients
Closed
Phase
Accrual
90%
Published
Abbreviated Title
Neoadjuvant Methotrexate, Cisplatin and Vinblastine (MCV) Followed by Concomitant Cisplatin/Radiotherapy for Unresectable Localized Bladder Cancer Patients
Activated
09/01/1987
Closed
08/15/1991
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1996
Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: A Phase I/II Southwestern Oncology Group study.
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase